AIM General Clinical Guideline
OPEN THE GENERAL CLINICAL GUIDELINE EFFECTIVE AUGUST 17, 2020
AIM Clinical Appropriateness Guidelines for Radiology
The foundation of our solution platform for specialty benefits management is our clinical appropriateness guidelines.
AIM Clinical Appropriateness Guidelines for Radiology are developed through a rigorous process integrating evidence-based literature with expert physician review. Included are guidelines for advanced imaging and nuclear medicine imaging.
AIM Clinical Appropriateness Guidelines for Advanced Imaging
Modalities addressed in the AIM Clinical Appropriateness Guidelines for Advanced Imaging include CT, MRI, MRA, PET, quantitative CT, and arterial ultrasound.
- Abdominal and pelvic imaging
- Brain imaging
- Chest imaging EFFECTIVE AUGUST 16, 2020 For Commercial and Medicare members
- Chest imaging EFFECTIVE MARCH 12, 2020 For Medicaid members
- Extremity imaging
- Head and neck imaging
- Oncologic imaging EFFECTIVE AUGUST 16, 2020 For Commercial and Medicare members
- Oncologic imaging EFFECTIVE NOVEMBER 10, 2019 For Medicaid members
- Spine imaging
- Vascular imaging EFFECTIVE MAY 17, 2020 For Commercial and Medicare members
- Vascular imaging EFFECTIVE NOVEMBER 10, 2019 For Medicaid members
AIM Clinical Appropriateness Guidelines for Nuclear Medicine Imaging
Modalities addressed in the AIM Clinical Appropriateness Guidelines for Nuclear Medicine Imaging include nuclear scintigraphy studies, gastric emptying, Meckel’s scan, radionuclide cisternography, and SPECT. For PET and myocardial perfusion imaging, see guidelines for brain imaging, oncologic imaging, and cardiac imaging.
OPEN THE NUCLEAR MEDICINE IMAGING GUIDELINES EFFECTIVE SEPTEMBER 1, 2020
Trouble viewing the guidelines?
To open our guidelines, your computer needs Adobe Reader, a free and trusted software that allows you to view PDFs.
CLINICAL GUIDELINES ACCESS
Accessing Clinical Guidelines and Cancer Treatment Pathways
By clicking on the “I accept” button below, I acknowledge I accept the following terms and conditions when accessing and using the Clinical Guidelines and Cancer Treatment Pathways:
AIM Specialty Health® (AIM) has developed proprietary Clinical Guidelines and Cancer Treatment Pathways (together with any updates, referred to collectively as the “Guidelines and Pathways”). The Guidelines and Pathways are designed to evaluate and direct the appropriate utilization of certain health care services. They are based on data from peer-reviewed scientific literature, from criteria developed by specialty societies, and from guidelines adopted by other health care organizations. Access to these Guidelines and Pathways is being provided for informational purposes only. Although AIM has a process for updating its Guidelines and Pathways on a regular basis, due to the rapidly evolving nature of medicine, these Guidelines and Pathways may not reflect the most current evidence on a particular service or treatment.
The Guidelines and Pathways are protected by copyright of AIM as permitted by and to the full extent of the law. These rights are not released, transferred, or assigned as a result of allowing access. You agree that you do not have any ownership rights to the Guidelines and Pathways and that you are expressly prohibited from selling, assigning, leasing, licensing, reproducing, or distributing the Guidelines and Pathways unless authorized in writing by AIM.
The Guidelines and Pathways do not constitute medical advice and/or medical care and do not guarantee results or outcomes. The Guidelines and Pathways are not a substitute for the experience and judgment of a physician or other health care professionals. Any clinician seeking to apply or consult the Guidelines or Pathways is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The Guidelines and Pathways do not address coverage, benefit, or other plan specific issues.
The Guidelines and Pathways are provided “as is” without warranty of any kind, either expressed or implied. AIM disclaims all responsibility for any consequences or liability attributable or related to any use, nonuse, or interpretation of information contained in the Guidelines.
About the AIM Clinical Appropriateness Guidelines for Genetic Testing
The AIM Clinical Appropriateness Guidelines for Genetic Testing (with any updates, referred to as the “Genetic Testing Guidelines”) were developed by and used with permission from Informed Medical Decisions, Inc.
The Genetic Testing Guidelines are protected by copyright of Informed Medical Decisions, Inc., as permitted by and to the full extent of the law. These rights are not released, transferred, or assigned as a result of allowing access. You agree that you do not have any ownership rights to the Genetic Testing Guidelines and that you are expressly prohibited from selling, assigning, leasing, licensing, reproducing, or distributing the Genetic Testing Guidelines unless authorized in writing by Informed Medical Decisions.
AIM and Informed Medical Decisions, Inc., disclaim all responsibility for any consequences or liability attributable or related to any use, nonuse, or interpretation of information contained in the Genetic Testing Guidelines.